Inhibitors of PD-1 (pembrolizumab, nivolumab, cemiplimab) or PDL-1 (atezolizumab, avelumab, durvalumab) induce tumor cell apoptosis and T cell activation. The gene discussed is CD274; the disease is neoplasm.